奥扎格雷钠联合阿司匹林、低分子肝素治疗进展性脑梗死的临床疗效评价

目的探讨奥扎格雷钠联合阿司匹林、低分子肝素治疗进展性脑梗死的临床疗效评价。方法选取2010年1月～2012年10月我院收治的220例进展性脑梗死患者，随机分成治疗组和对照组各110例。对照组给予低分子肝素5000U皮下注射q12h，应用7～10d，同时给予阿司匹林肠溶片100～300mg口服qd；治疗组在上述药物的基础上加用奥扎格雷钠80mg入液静滴bid，持续14d为一个疗程。严密监测两组患者的各项指标，比较两组的临床疗效和安全性。结果（1）治疗组进展性脑梗死患者的总有效率（84．5％）与对照组的总有效率（72．7％）相比较差异有统计学意义（x^2=4．130，P=0.048〈0．05）；（2）治疗组进展性脑梗死患者在14d后神经功能评分（8．24±0．29）明显低于治疗前（t=7．921，P=0.013〈0．05），与对照组比较没有显著性差异。结论奥扎格雷钠联合阿司匹林、低分子肝素是治疗进展性脑梗死患者有效、安全的药物，可以在临床上推广使用。

Clinical efficacy evaluation of sodium ozagrel combined with aspirin and low molecular heparin in treatment of progressive cerebral infarction

Objective To discuss the clinical curative effect of sodium ozagrel combined with aspirin and low molecular heparin in treatment of progressive cerebral infarction. Methods All of 220 patients with progressive cerebral infarction choosed in our hospital from January 2010 to October 2012 were randomly divided into the treatment group and the control group, each group had 110 cases. The control group were given 5000U low molecular heparin subcutaneous injection,ql2h, 7-10 days, and 100-300 mg oral aspirin enteric-coated tablet, qd; On the basis of above drugs, the treatment group were added 80 mg sodium ozagrel intravenous drip, bid, 14 days were a treatment course. The indicators of patients in the two groups were closely monitored, and the clinical efficacy and safety of the two groups were compared. Results （1）The total effective rate of patients with progressive cerebral infarction in the treatment group was 84.5%, the control group was 72.7%, and the difference was statistically significant （x^2=4.130 ,P=0.048〈 0.05）; （2）The neurological functional scoring of patients with progressive cerebral infarction in the treatment group after 14 days （8.24±0.29） was obviously lower than that before treatment （t=7.921 ,P=0.013〈0.05）, and there was no significant difference compared with the control group. Conclusion Sodium ozagrel combined with aspirin and low molecular heparin are effective and safe drugs for progressive cerebral infarction, and may be used widely in clinically.